U.S., July 21 -- ClinicalTrials.gov registry received information related to the study (NCT07713290) titled 'A Phase 1b Study of GKL-006 Injection in Patients With Unresectable Hepatocellular Carcinoma' on June 12.
Brief Summary: This is a Phase 1b study of GKL-006 Injection in patients with unresectable hepatocellular carcinoma.
Study Start Date: April 03, 2025
Study Type: INTERVENTIONAL
Condition:
Hepatocellular Carcinoma (HCC)
Unresectable Hepatocellular Cancer
Intervention:
DRUG: GKL-006 Injection
An iNKT cell therapy
PROCEDURE: Transarterial chemoembolization (TACE)
A standard locoregional therapy for hepatocellular carcinoma
Recruitment Status: ACTIVE_NOT_RECRUITING
Sponsor: Beijing Gene Key Life Technology Co., Ltd
Discl...